32 results about "Anti metabolites" patented technology

An anti-hepatitis C agent which is an anti-metabolite to the host and cannot be administered on a daily or chronic basis as is usual in anti-viral therapy (referred to below as an “anti-HCV anti-metabolite”), can be administered using a traditional anti-cancer dosing regimen (for example via intravenous or parenteral injection), over a period of one, two, three, four, five, six, or seven days followed by cessation of therapy until rebound of the viral load is noted. This dosing regimen runs counter to conventional antiviral experience, wherein effective agents are usually administered over at least fourteen days of sustained therapy, and typically on an indefinite daily basis.

Disclosed herein are methods of using glucose anti-metabolites to alter utilization of glucose or other energy sources and to mimic metabolic effects of caloric restriction. In particular, in one embodiment herein, methods of enhancing longevity in an animal are described, the methods comprising administration of a composition comprising a glucose anti-metabolite to the animal. In another embodiment, methods of enhancing longevity in an animal are described, the methods comprising administration of a composition comprising avocado extract, wherein the avocado extract comprises mannoheptulose. In yet another embodiment, methods of enhancing longevity in an animal are described, the methods comprising administration of a composition comprising mannoheptulose.

The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to decrease a level of an oxidized glutathione and / or increase the ration of reduced glutathione to oxidized glutathione in the blood of the mammal subsequent to administration of the glucose anti-metabolite.

The present invention is a bone growth stimulating and promoting cytokine type biological implant preferably comprising PTH coated with a controlled release biodegradable coating that is implanted preferably in the concave side of a scoliotically curved spine in combination with a bone growth inhibiting type biological implant preferably comprising methotrexate or like anti-metabolite coated with a controlled release biodegradable coating that is implanted preferably in the convex side of a scoliotically curved spine. The insertion of the biological implant is highly non-invasion, especially as compared to more conventional spine surgical methods, and the biological implant does not decrease spinal mobility or spinal range of motion.

Disclosed is an anticancer slow release agent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer antibiotics are selected from Idarubicin, Valtaxin, Pirarubicin and Mitoxantrone, The anti-metabolite drugs are selected from Pemetrexed, Carmustine, Tegafur, Zalcitabine, Emtritabine, Galocitabine, Ibacitabine, Ancitabine, Decitabine, Flurocitabine, Enocitabine, Imidazoletabine, Capecittabine, Gemcitabine, Fludrarbine, Raltitrexed, Dexrazoxane, Cladribine, Nolatrexed and folic acid, The slow release auxiliary materials are selected from EVAc, Polifeprosan, sebacylic acid copolymer, lactic acid, the viscosity of the suspension adjuvant is 100-3000cp (at 25-30 deg C), and is selected from sodium carboxymethylcellulose. The slow release microspheres can also be prepared into slow release implanting agent for injection or placement in or around tumor.

Methods of maintaining and / or attenuating a decline in the quality of life of a mammal comprising the step of administering to the mammal a composition comprising an effective amount of mannoheptulose wherein the effective amount of mannoheptulose provides a dosage to the mammal on a daily basis from about 0.001 gram per kilogram of body weight of the mammal to about 1 gram per kilogram of body weight of the mammal.

A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.

The invention provides a sustained-release injection which is an anti-tumor composite containing taxanes drug and bortezomib. The sustained-release injection comprises a sustained-release microsphere and a solution medium, wherein the sustained-release microsphere comprises effective anti-tumor ingredient and sustained-release excipient, the solution medium is a common solution medium or a special solution medium containing a suspending drug. The suspending drug has the viscosity between 100cp and 3000cp (under twenty centi degrees to thirty centi degrees) and is selected from sodium carboxymethylcellulose and others; the effective anti-tumor ingredient comprises the anti-metabolite drug and / or the combination thereof; the taxanes drug is selected from Taxol, Docetaxel, EPI-Taxol or Hydroxy-Taxol; the sustained-release excipient is selected from polyphosphonate copolymer like p(LAEG-EOP)or p(DAPG-EOP), PLA, PLGA, polyphosphonate with PLA, polifeprosan and the polymer or blending polymer of ( erucic acid dipolymer-sebacic acid) or poly(boletic acid-sebacic acid); the anti-tumor composite can also be prepared to be a sustained-release implant which can maintain the effective concentration of drug over forty days for intratumor or tumor circumference injection or placement, can also reduce general reaction obviously and enhance the treatment effect of non-operative therapeutics such as chemotherapy and radiotherapy.

The present invention is a bone growth stimulating and promoting cytokine type biological implant preferably comprising PTH coated with a controlled release biodegradable coating that is implanted preferably in the concave side of a scoliotically curved spine in combination with a bone growth inhibiting type biological implant preferably comprising methotrexate or like anti-metabolite coated with a controlled release biodegradable coating that is implanted preferably in the convex side of a scoliotically curved spine. The insertion of the biological implant is highly non-invasion, especially as compared to more conventional spine surgical methods, and the biological implant does not decrease spinal mobility or spinal range of motion.

The invention pertains to methods for treating ectopic pregnancy. More particularly, the present invention relates to methods for treating unruptured ectopic pregnancy using a non-surgical method comprising the administration of an EGFR inhibitor alone or in combination with an anti-metabolite e.g. methotrexate (MTX). The methodology is potentially applicable to treatment of unruptured ectopic pregnancies of all sizes.

A method for treating cancer includes administering to a subject in need of the treatment an anticancer agent composition that includes the following agents as active ingredients; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.

The invention discloses application of paeoniflorin-6-O'-benzenesulfonate. The application refers to application in preparation of preparations for preventing and / or treating renal injuries induced byantitumor drugs. The antitumor drugs comprise alkylating agents, anti-metabolites, antibiotics or metal platinum antitumor drugs. Researches prove that the paeoniflorin-6-O'-benzenesulfonate disclosed by the invention has an effect of protecting the renal injuries induced by antitumor drugs, is capable of improving renal injuries and maintaining and restoring renal functions, and is safe and effective.

The invention provides a method of improving the immunity of a companion animal. The method can include administering to the companion animal a glucose anti-metabolite. The glucose anti-metabolite can be 2-deoxy-D-glucose; 5-thio-D-glucose; 3-O-methylglucose; 1,5-anhydro-D-glucitol; 2,5-anhydro-D-glucitol; 2,5-anhydro-D-mannitol; mannoheptulose; and mixtures and combinations thereof. The companion animal can be a dog or a cat. Improving the immunity can include altering the proliferative ability of T and B immune cells, and altering the relative distribution of immune cell phenotypes, for example.

The invention pertains to methods for treating ectopic pregnancy. More particularly, the present invention relates to methods for treating unruptured ectopic pregnancy using a non-surgical method comprising the administration of an EGFR inhibitor alone or in combination with an anti-metabolite e.g. methotrexate (MTX). The methodology is potentially applicable to treatment of unruptured ectopic pregnancies of all sizes.

The present invention relates to the use of an alkanoyl L-carnitine selected from the group consisting of acetyl, propionyl, valeryl, isovaleryl and butirryl L-carnitine; in combination with one or more chemotherapeutic agent selected from the group consisting of: a camptothecin derivative; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; toxins; and imides; for the treatment of neoplasms.

A method for treating cancer includes administering to a subject in need of the treatment an anticancer agent composition that includes the following agents as active ingredients; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

The invention provides a sustained-release injection which is an anti-tumor composite containing anti-metabolite drug and bortezomib. The sustained-release injection comprises a sustained-release microsphere and a solution medium, wherein the sustained-release microsphere comprises effective anti-tumor ingredient and sustained-release excipient, the solution medium is a common solution medium or a special solution medium containing a suspending drug. The suspending drug has the viscosity between 100cp and 3000cp (under twenty centi degrees to thirty centi degrees) and is selected from sodium carboxymethylcellulose and others; the effective anti-tumor ingredient comprises the anti-metabolite drug and / or the combination thereof; the sustained-release excipient is selected from polyphosphonate copolymer like p(LAEG-EOP)or p(DAPG-EOP), PLA, polyphosphonate with PLA, polifeprosan, copolymer of dual fatty acid and sebacic acid, the polymer or blending polymer of ( erucic acid dipolymer-sebacic acid) or poly(boletic acid-sebacic acid); the anti-tumor composite can also be prepared to be a sustained-release implant which can maintain the effective concentration of drug over forty days for intratumor or tumor circumference injection or placement, can also reduce general reaction obviously and enhance the treatment effect of non-operative therapeutics such as chemotherapy and radiotherapy.

The present invention relates to a use of composition comprising a glucose anti-metabolite and / or source of glucose anti-metabolite in a method of enhancing a positive affect and / or energetic arousal in a mammal.

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of an agent selected from an anti-metabolite agent or analog thereof and combinations thereof; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.

A composition including a glucose anti-metabolite, BHA, and / or BHT. The composition can be for a companion animal. The composition can be a nutritionally balanced pet food composition.

The invention discloses novel purine analogue tetrazole (1, 5-a) pyrimidine-5, 7-diol (compound I) and a synthetic route thereof. Pharmacological experiments show that the compound I is inhibitory for cell division cycle phosphoesterase CDC25. The compound I can be made into anti-metabolites high in bioactivity, fine in selectivity and low in toxicity, and is widely applicable to the clinic.

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of an agent selected from an anti-metabolite agent or analog thereof and combinations thereof; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.

The invention relates to a solid tumor resistant combined medicine with topoisomerase inhibitor, which comprises anti-cancer effective ingredients and medical auxiliary materials, wherein, the anti-cancer effective ingredients comprise topoisomerase inhibitor and topoisomerase inhibitor synergistic agent; the topoisomerase inhibitor synergistic agent mainly comprises paclitaxel anti-cancer medicines and / or antitumor antibiotics and / or anti-metabolite; the medical auxiliary materials mainly comprises biological soluble, degradable and absorbable macromolecule polymer, which enables to release the anti-cancer medicine slowly on the tumor in the degradation and absorption process, and thereby reduce the body toxic reaction obviously and maintain the effective medical concentration on the tumor at the same time. The solid tumor resistant combined medicine has the advantages of reducing the body toxic reaction, selectively improving the medical concentration on the tumor and enhancing the treatment effect of chemotherapeutics, radiation therapy and other non-surgery treatments.